These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 30695320)

  • 1. [Familial Hypercholesterolemia and Its Related Molecules].
    Ogura M
    Rinsho Byori; 2016 Jun; 64(6):657-666. PubMed ID: 30695320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the pharmacological management of hypercholesterolaemia.
    Ajufo E; Rader DJ
    Lancet Diabetes Endocrinol; 2016 May; 4(5):436-46. PubMed ID: 27012540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibition in the management of familial hypercholesterolemia.
    Ogura M
    J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
    Papademetriou V; Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Dimitriadis K; Tsioufis K
    Curr Pharm Des; 2018; 24(31):3647-3653. PubMed ID: 30317985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
    Patel RS; Scopelliti EM; Savelloni J
    Pharmacotherapy; 2015 Dec; 35(12):1189-203. PubMed ID: 26684558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
    Hopkins PN; Krempf M; Bruckert E; Donahue S; Yang F; Zhang Y; DiCioccio AT
    J Clin Lipidol; 2019; 13(6):970-978. PubMed ID: 31767518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
    Thiery J; Burkhardt R
    Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
    El Khoury P; Elbitar S; Ghaleb Y; Khalil YA; Varret M; Boileau C; Abifadel M
    Curr Atheroscler Rep; 2017 Oct; 19(12):49. PubMed ID: 29038906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
    Ito MK; Watts GF
    Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.